GlobeNewswire

MedDay Appoints Industry Leader Christian Chavy as Chief Executive Officer

Del

Dr. Frédéric Sedel to Transition to CSO

PARIS, July 26, 2018 (GLOBE NEWSWIRE) -- MedDay, a pioneering pharmaceutical company focused on the treatment of nervous system disorders, today announces the appointment of Christian Chavy MBA as Chief Executive Officer, effective 27th August 2018.

Mr. Chavy will succeed Dr. Frédéric Sedel, CEO and Co-Founder of MedDay, who will remain in his existing role until August 27th.  Dr. Sedel will then transition to Chief Scientific Officer and continue to serve on the board of directors.

Commenting on the appointment, Catherine Moukheibir, Chairman of the board, said, "We are thrilled to have Christian take on the role of CEO at this critical time for MedDay as we execute on our confirmatory Phase III clinical trial of MD1003 in progressive MS and make preparations to become a commercial stage company." 

"On behalf of the Board of Directors, I would also like to thank Dr. Frédéric Sedel, our co-founder, who has been instrumental in building MedDay into the company that it is today and has laid the groundwork for a company that ultimately should bring innovative treatments for patients," continued Mrs. Moukheibir. "Under his leadership, MedDay has advanced our lead candidate MD1003 into late stage clinical development, including completion of a successful Phase III trial in progressive MS, and is building a pipeline of promising candidates to treat CNS diseases.  The appointment of Christian Chavy represents a continuation of this strategy. We look forward, also, to further contributions from Frédéric Sedel in his new role as Chief Scientific Officer."

Mr. Christian Chavy commented, "I am honored to be appointed CEO of MedDay.  MD1003, which has a novel mechanism of action and which has already demonstrated strong clinical activity, is positioned to transform the treatment paradigm for progressive multiple sclerosis. We look forward to completing the Phase III trial and see a clear path to approval in the major markets, including U.S. and EU. MedDay is also dedicated to finding effective treatments for severe diseases of the nervous system through our pioneering work of targeting brain metabolism."

Dr. Frédéric Sedel commented, "I am convinced that Christian Chavy has the right skill set and vision to bring MedDay to the next stage. I am very excited with my new role as company CSO which I believe is the area where I can create the most value."

Mr. Chavy is a highly accomplished pharmaceutical executive with experience in Europe and North America. Most recently, he was the CEO of Stallergenes (2014-2016) and Partner at Ares Life Sciences (2010-2014).  His career highlights include 9 years at Actelion Pharmaceuticals (2000-2009) where he was promoted to President of Global Operations, with responsibility over USA, Europe, Japan and rest of the world. Prior to joining Actelion, he was VP, Head of the reproductive health commercial unit at Serono in Geneva and Chairman of Serono's French subsidiary. He also spent five years at Groupe Rhône Poulenc Rorer as its Chairman in Canada, having previously been Chairman and CEO of Rorer France.  Earlier in his career he held roles of increasing responsibility at Bristol-Myers France, SmithKline and French Laboratories, and Merck Sharpe & Dohme.

Mr. Chavy is currently chairman of the board of Ixaltis, a specialty pharmaceutical company developing innovative treatment for genitourinary tract disorders that he founded, and serves on the board of Cerenis. He is a graduate of the Ecole Supérieure des Sciences Economiques et Commerciales (ESSEC) and the Institut de Contrôle de Gestion (ICG).

About MedDay
MedDay is a pioneering pharmaceutical company targeting brain metabolism to treat nervous system disorders. The company was founded in 2011.  The lead product, MD1003 is a formulation of high dose Pharmaceutical grade Biotin (hdPB) developed for progressive multiple sclerosis and other demyelinating diseases. The R&D pipeline also includes MD1103 in autism spectrum disorders and MD1105 in Alzheimer's disease.

MedDay explores brain metabolic pathways through its metabolomics research platform, SPECMET, which supports the discovery of additional pipeline assets. SPECMET screens cerebrospinal fluid (CSF) from patients with various Central Nervous System (CNS) disorders to identify the disrupted metabolic pathways. Compounds that are known to affect these metabolic pathways are then identified and further developed. SPECMET was developed in collaboration with the Commissariat à l'Energie Atomique (CEA) and in March 2017, MedDay acquired the health division of Profilomic SA, an innovative company formed out of the CEA in 2010, which significantly strengthened MedDay's research capabilities as the company aims to expand its pipeline.

MedDay is well funded by investors including Sofinnova Partners, InnoBio, Andera Partners and Bpifrance Large Venture. MedDay is headquartered in Paris and has a team in Boston.

For more information, please see: www.medday-pharma.com. Follow us on Twitter: @MedDayPharm.

Contact information:
MedDay Pharmaceuticals
Email: contact@medday-pharma.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MedDay Pharmaceuticals S.A. via Globenewswire

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Qtum Launches Enterprise Blockchain Solution — Unita24.4.2019 10:00:00 CESTPressemelding

SHANGHAI, China, April 24, 2019 (GLOBE NEWSWIRE) -- Qtum, the open-source public blockchain platform, launched Unita, a blockchain protocol designed for enterprises. Unita securely stores data, utilizes existing developer tools and automates information transfer processes for businesses at a groundbreaking speed of 10,000 transactions per second. Unita’s flexibility allows a wide population of developers to use common tools to solve the biggest problems businesses face when considering adopting blockchain technology, including consumer data regulations and verification. Unita takes advantage of an innovative, unique, and scalable consensus algorithm, SCAR, that allows parameter adjustments to take place on the blockchain. The dynamic nature of SCAR saves substantial amounts of disk space, bandwidth, and other network resources. Miguel Palencia, Chief Information Officer of the Qtum Foundation, said: “Speed and customization are two of the main barriers for enterprises looking to adopt

Percona Names Martin James Vice President of Sales EMEA & APAC24.4.2019 09:00:00 CESTPressemelding

James Brings Over 25 Years of Sales Management Experience to Percona RALEIGH, N.C., April 24, 2019 (GLOBE NEWSWIRE) -- Percona , a leader in open source database software and services, has named Martin James vice president of sales for the EMEA and APAC regions. With more than 25 years of experience building and leading sales teams in Europe, James will be responsible for the entire Percona EMEA sales operation, including direct sales, business development and partner channels. Percona is a leader in providing best-of-breed, enterprise-class support, consulting, managed services, training and software for MySQL, MariaDB, MongoDB, PostgreSQL and other open source databases in on-premises and cloud environments. An unbiased, trusted partner, Percona provides single-source expertise in multi-vendor environments that eliminates lock-in, increases agility and enables business growth. Prior to joining Percona, James was the regional vice president of Northern Europe for open source database

Colruyt Group Selects Juniper Networks to Support its Digital Transformation24.4.2019 09:00:00 CESTPressemelding

Network Underpins Fast Business Growth for Retail Leader SUNNYVALE, Calif., April 24, 2019 (GLOBE NEWSWIRE) -- Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, today announced that Colruyt Group, one of the largest retailers in Belgium and France, has deployed Juniper Networks’ solutions to improve its data connectivity in response to exponential growth in network traffic. Colruyt Group consists of more than 40 brands for consumers and businesses, including food and non-food retail, fuel, wholesale and food services. Established more than 80 years ago, it operates 553 of its own stores, supplies 581 independent shopkeepers in Belgium and France and also offers its products via e-commerce sites. The group owns the BIO-planet, Collishop, Cru, dreambaby, DreamLand, OKay, SPAR Belgium, MyUnderwear24, NewStory, Newpharma and ZEB brands and operates a network of DATS24 fuel stations throughout Belgium. Colruyt must ensure that it provides quality

ADC Therapeutics and Adagene Announce License Agreement24.4.2019 07:00:00 CESTPressemelding

ADC Therapeutics to develop next-generation masked antibody drug conjugates (ADCs), incorporating Adagene’s SAFEbody ™ technology, with potential utility across multiple tumor types Collaboration enables focus on targets in which healthy tissue expression precludes development of ADCs incorporating traditional antibodies LAUSANNE, Switzerland and SUZHOU, China, April 24, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), and Adagene Inc., an antibody engineering and discovery company, today announced that they have entered into a discovery collaboration and license agreement. ADC Therapeutics will use Adagene’s SAFEbody™ technology to generate a masked antibody that will be combined with ADC Therapeutics’ pyrrolobenzodiazepine (PBD) cytotoxic payload technology for the development of a novel ADC against a solid tumor target. Adagene has developed the SAFEbody t

Media Advisory: Bombardier to Report its First Quarter 2019 Financial Results and to Hold its Annual Meeting of Shareholders on Thursday, May 223.4.2019 22:54:00 CESTPressemelding

MONTRÉAL, April 23, 2019 (GLOBE NEWSWIRE) -- Bombardier (TSX: BBD.B) will publish its financial results for the first quarter of 2019 and hold its annual meeting of shareholders at the Grand Quay (former Alexandra Pier) located in Montréal’s Old Port on Thursday, May 2, 2019. Quarterly conference call On May 2 at 8:00 a.m., EDT, Bombardier’s management will hold a webcast/conference call intended for investors and financial analysts to review the company’s financial results for the first quarter of 2019. Please find below the dial-in information for the call: In English: 514 394 9320 or 1 866 240 8954 (toll-free in North America) +800 6578 9868 (overseas calls) In French: 514 394 9316 or (with translation) 1 888 791 1368 (toll-free in North America) +800 6578 9868 (overseas calls) Annual meeting of shareholders WHERE: Grand Quay, 200 de la Commune Street West, Montréal, Québec, H2Y 4B2 WHEN: Thursday, May 2, 2019 Media registration: 9:30 a.m. - 10:15 a.m. Eastern Daylight Time (EDT) Op

Patton Enhances Cloud Orchestration Service with OA&M Messaging23.4.2019 20:05:00 CESTPressemelding

Expanding its virtualized NMS with alerts and notifications sent to mobile teams, Patton reduces operational expense and complexity for service providers SmartNode VoIP… More than Just Talk! GAITHERSBURG, Md., April 23, 2019 (GLOBE NEWSWIRE) -- Patton Electronics—creator of SmartNode virtual VoIP CPE and CopperLink Ethernet and power-over-Ethernet extenders—has enhanced its revolutionary Patton Cloud virtualized edge-orchestration service by adding new alerts and notifications capabilities, the company announced today. WATCH the VIDEO TUTORIAL Patton Cloud Alerts and Notifications Added alerting and notification capabilities augment the Patton Cloud with fault and performance-monitoring tools for service-quality assurance, as well as device and service management. The Patton cloud already provides automated onboarding and provisioning as part of its full-service, life-cycle orchestration solution. Now, element status, statistics, faults, alerts, and alarms can all be delivered to techn